Accelerating Biomedical Discoveries into Clinical Treatments
Translating research into new innovative therapies and treatments is a driving force for the Biomarkers and Genes research theme at the Medical School.
Translating research into new innovative therapies and treatments is a driving force for the Biomarkers and Genes research theme at the Medical School.
Research scientists employ a wide range of approaches from laboratory, mass spectrometry, computer modelling, and epidemiological studies to applied problems in the identification and use of biomarkers.
Working with the British Heart Foundation Cymru and expert researchers from across the world, the Medical School is developing new treatments for heart disease and helping improve the clinical management of patients. The Medical School has strong partnerships with clinicians, engineers and computer scientists from across Swansea University cementing it as Wales’s home for cardiovascular research.
With more than 20 Principal Investigators, the Medical School is also accelerating biomedical discoveries into clinical treatments for other major diseases, including neurological disorders, diabetes and cancer - with a strong focus on nanotoxicology.
The Biomarkers and Genes theme has been key to much of our translation impact when it comes to improving outcomes for patients and insights for medical and public health professionals.
Our identification, understanding and use of Biomarkers coupled with world leading expertise in Genes allows us to continue to have significant impact upon the world’s premiere global health challenges, building upon our pioneering research contributions in genetic toxicology, DNA repair mechanisms, and the genetics of microbes and cell organelles.
The value of Self-Monitoring of Blood Glucose (SMBG) in people with non-insulin treated T2D has been debated for many years with current UK guidelines limiting its use. We led a study across Wales and England to evaluate ‘Structured SMBG’ and demonstrated that it can provide clinically significant improvements in blood glucose control. We also found that it improved an individual’s quality of life. This evidence demonstrates that SMBG is a useful aide in diabetes self-management.
Parkinson's disease (PD) is a degenerative disorder of the central nervous system. We and others have previously shown that endogenous cholesterol metabolites are key factors for neurogenesis and neuronal survival. We currently study the function and mechanism of action of specific cholesterol metabolites that are up- or down-regulated in PD patients. Our aim is to utilise these metabolites as well as related compounds to ameliorate PD symptoms in rodent models of PD.
The critical mass of the Biomarkers and Genes theme comes from 4 key and distinct sub-themes, these sub-themes contribute to the collaborative and innovative culture of the Medical School’s research, each attracting significant and prestigious investment and a wealth of PhD and other research students.